Corporate Banner
Satellite Banner
Automation & Microfluidics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Sagentia Selected by PathoGenetix to Develop Commercial-Scale, Rapid Microbial Detection System

Published: Wednesday, January 11, 2012
Last Updated: Wednesday, January 11, 2012
Bookmark and Share
The system is being designed to capitalize on the broad range of potential GSS applications that span microbial genomics research, food and product safety, and clinical infectious disease testing.

PathoGenetix’s proprietary GSS technology combines automated sample preparation and single molecule detection making it possible to detect and characterize microbes from complex biological samples in as little as three hours. Specifically, the technology extracts genomic barcodes from microbial DNA as it flows through a microfluidic chip at 150 million base pairs per second. A universal reagent set decorates the DNA enabling specific pathogens to be identified by comparing their unique DNA ‘barcode’ with PathoGenetix’s own library of templates. With this approach, it is possible to identify thousands of different microbial strains through a single test, days faster and at far lower cost than current techniques. The GSS technology was developed with more than $50 million in support from the United States Departments of Defense and Homeland Security under advanced biosensor programs.

Sagentia, an experienced leader in the development of new technologies and breakthrough products, including complex diagnostics, was brought in to the project to take the current laboratory prototype and help turn it into a technically and commercially successful platform. Sagentia’s work will include further integration of state-of-the-art optics and microfluidics, making the technology more robust, enhancing the usability of the system, driving cost reduction, and increasing manufacturing efficiency.

“Sagentia’s commitment to PathoGenetix directly reflects our mission to help clients develop and deliver innovative technologies through all the stages of device development,” said Brent Hudson, chief executive officer of Sagentia. “Working across the complete product development continuum - from market needs analysis to transfer to volume manufacturing - we make it possible for companies to take complex ideas and develop them into products that are robust and usable in many settings. We are excited to work with PathoGenetix and look forward to helping them bring this groundbreaking new technology to market.”

“We are very excited to be working with Sagentia on this critical initiative,” said John Canepa, chief executive officer of PathoGenetix. “At PathoGenetix, we are focused on revolutionizing microbial identification and diagnostics. We chose Sagentia because of the company’s extensive technical knowledge and the team’s understanding of our core objectives. We believe that Sagentia’s team will add tremendous value to this project and we look forward to working with them to bring to market an instrument platform that will improve the speed and efficacy in a range of diagnostics applications.” He added that PathoGenetix expects to launch the system’s initial commercial application, for the research market, in late 2012.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Diagnostic Thread - Weaving the Future?
Researchers have created diagnostic threads that could pave the way for next-gen implantable and wearable diagnostics.
R&D Agreement for Development of CtDNA Diagnostics
SeraCare and NIST partner for development of ctDNA diagnostic assay reference materials.
Adipose Analysis on Microfluidic Chips
Scientists have developed a microfluidic chip the works with minute liquid quantities to grow and study cells.
New Device can Study Electric Field Cancer Therapy
Microfluidic device allows study of electric field cancer therapy through low-intensity fields, preventing malignant cells spreading.
DNA Production Facility Begins Operation
Scientists mark the opening of the UK's first fully automated DNA construction and modification facility.
A “Micro Winery” That Makes Wine Continuously
An American professor, working in collaboration with EPFL, is developing a miniature device for producing wine non-stop and testing different fermentation processes.
Testing for Malaria or Cancer at Home
Chemist develops tech to save lives in rural Africa.
Tough New Hydrogel Hybrid Doesn’t Dry Out
Water-based material could be used to make artificial skin, longer-lasting contact lenses.
Lasers Carve the Path to Tissue Engineering
A new technique, developed at EPFL, combines microfluidics and lasers to guide cells in 3D space, overcoming major limitations to tissue engineering.
A Future Tool for Medicine, Food Safety
A new type of electronic sensor that might be used to quickly detect and classify bacteria for medical diagnostics and food safety has passed a key hurdle by distinguishing between dead and living bacteria cells.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!